$RLFTF
2.11B outstanding, no worries, I suspect a significant amount may be held by it's parent company, Therametrics Discovery AG. https://www.dnb.com/business-directory/compan...-companies
https://www.acxit.com/en/therametrics-relief/
The trials are being done in conjunction with NeuroRx, whose principal's bio is below, what an impressive background.
Chief Executive Officer Jonathan C. Javitt, M.D., M.P.H.
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.
See his interview here -
https://www.youtube.com/watch?v=lgmpS2N8124
Here's a look at the patent - https://patents.google.com/patent/US8178489B2...=aviptadil
Below are some excerpts.
The Aviptadil formulation of the present invention may also be lyophilized (freeze-dried). The lyophilized product can then be rehydrated before use.
The liquid pharmaceutical formulations can also be lyophilized. The shelf-life of the lyophilized formulation was at least 1 year at 25° C. Aviptadil can also be minimal formulated with mannitol or with mannose.
The liquid pharmaceutical compositions according to the current invention are suitable for the manufacturing of a medicament for the prophylaxis and/or treatment of autoimmune diseases comprising bronchial asthma, rheumatoid arthritis, lupus, scleroderma, Sjogren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis, type I diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, acute disseminated encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, and sarcoidosis
Also Therametrics popped 150% today also.
https://finance.yahoo.com/quote/0QKQ.L/profile?p=0QKQ.L
2.11B outstanding, no worries, I suspect a significant amount may be held by it's parent company, Therametrics Discovery AG. https://www.dnb.com/business-directory/compan...-companies
https://www.acxit.com/en/therametrics-relief/
The trials are being done in conjunction with NeuroRx, whose principal's bio is below, what an impressive background.
Chief Executive Officer Jonathan C. Javitt, M.D., M.P.H.
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.
See his interview here -
https://www.youtube.com/watch?v=lgmpS2N8124
Here's a look at the patent - https://patents.google.com/patent/US8178489B2...=aviptadil
Below are some excerpts.
The Aviptadil formulation of the present invention may also be lyophilized (freeze-dried). The lyophilized product can then be rehydrated before use.
The liquid pharmaceutical formulations can also be lyophilized. The shelf-life of the lyophilized formulation was at least 1 year at 25° C. Aviptadil can also be minimal formulated with mannitol or with mannose.
The liquid pharmaceutical compositions according to the current invention are suitable for the manufacturing of a medicament for the prophylaxis and/or treatment of autoimmune diseases comprising bronchial asthma, rheumatoid arthritis, lupus, scleroderma, Sjogren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis, type I diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, acute disseminated encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, and sarcoidosis
Also Therametrics popped 150% today also.
https://finance.yahoo.com/quote/0QKQ.L/profile?p=0QKQ.L
